The concurrence of diabetes mellitus and gallstone disease


Cite item

Full Text

Abstract

The article presents an update on the concurrence of diabetes mellitus (DM) and gallstone disease (GSD), on the mechanisms for the development of GSD in patients with type 2 DM (T2DM), on the risk factors of DM in GSD. The role of diabetic autonomic neuropathy of the gallbladder in the development of cholelithiasis is assessed in patients with T2DM. The impact of impaired secretion of neurohormones in the gastrointestinal tract in the development of DM in GSD is analyzed.

References

  1. Pagliarulo M, Fornari F, Fraquelli M. Gallstone disease and related risk factors in a large cohort of diabetic patients. Dig Liver Dis. 2004;36(2):130-134.
  2. Tsai C-J, Leitzmann MF, Willett WC. Macronutrients and Insulin Resistance in Cholesterol Gallstone Disease. Am J Gastroenterol. 2008;103:2932-2939.
  3. Chapman BA, Wilson IR, Frampton CM. Prevalence gallbladder disease in diabetes mellitus. Dig Dis Sci. 1996;41(11):2222-2228.
  4. Grosse H, Brauner G. The Risk of Diabetes after Existing Cholecystectomy. Z Gesamte Inn Med. 1978;33(8):247-249.
  5. Wang W, Li N. The Association of Gallstone Disease and Diabetes Mellitus. Saudi Med J. 2014;35(9):1005-1012.
  6. Laura M, Stinton Е, Eldon A. Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer. Gut Liver. 2012;6(2):172-187.
  7. Lai HC, Tsai IJ, Chen PC. Gallstones, a cholecystectomy, chronic pancreatitis, and the risk of subsequent pancreatic cancer in diabetic patients: a population-based cohort study. J Gastroenterol. 2013;48(6):721-727.
  8. Grigor’eva IN, Maliutina SK, Voevoda MI. Role of hyperlipidemia in cholelithiasis. Eksp Klin Gastroenterol. 2010;(4):64-68.
  9. Григорьева И.Н., Логвиненко Е.В., Ямлиханова А.Ю. Взгляд на желчнокаменную болезнь через призму метаболического синдрома (обзор литературы). Бюллетень СО РАМН. 2011;5(31):72-78.
  10. Liu С, Hsu С, Li С. A population-based cohort study of symptomatic gallstone disease in diabetic patients. World J Gastroenterol. 2012;18(14):1652-1659.
  11. De Santis A, Attili AF, Ginanni CS. Gallstones and Diabetes: a Case-control Study in afree-living Population Sample. Hepatology. 1997;25:787-790.
  12. Gaur C, Mathur A, Agarwal A. Diabetic autonomic neuropathy causing gall bladder dysfunction. J Assoc Physicians India. 2000;48(6):603-605.
  13. Kayacetin E, Kisakol G, Kaya A. Real-time sonography for screening of gallbladder motility in diabetic patients: relation to autonomic and peripheral neuropathy. Neuro Endocrinol Lett. 2003;24(1-2):73-76.
  14. Дедов И.И., Шестакова М.В. Сахарный диабет: диагноз, клиника, лечение, профилактика. М.; 2011.
  15. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. Учебное пособие. 2-е издание, переработанное и дополненное. М.: ГЭОТАР-Медиа; 2014:1032.
  16. Савельев В.С., Петухов В.А. Липидный дистресс-синдром. М.: Макс Пресс; 2010:18.
  17. Догадин С.А., Цуканов В.В., Селиверстова Е.В. Показатели липидного состава сыворотки крови и желчи при заболеваниях желчевыводящих путей у больных сахарным диабетом. Терапевтический архив. 2005;2(77):15-18.
  18. Цуканов В.В., Селиверстова Е.В., Догадин С.А. Клинические и биохимические характеристики заболеваний желчевыводящего тракта у пациентов с сахарным диабетом. Клиническая медицина. 2005;4(83):40-42.
  19. Scragg RK, Calvert GD, Oliver JR. Plasma lipids and insulin in gall stone disease: a case-control study. Br Med J. (Clin. Res. Ed). 1984;289(6444):521-525.
  20. Мансуров Х.Х., Мироджов Г.К., Мансурова Ф.Х. Инсулинорезистентность у больных метаболическим синдромом и желчнокаменной болезнью. Клиническая медицина. 2005;7(83): 48-51.
  21. Ивашкин В.Т. Гастроэнтерология. Национальное руководство. М.: ГЭОТАР-Медиа; 2008.
  22. Tung TH, Ho HM, Shih HC. A population-based follow-up study on gallstone disease among type 2 diabetics in Kinmen, Taiwan. World J Gastroenterol. 2006;12(28):4536-4540.
  23. Chien WH, Liu JH, Hou WY. Clinical implications in the incidence and associated risk factors of gallstone disease among elderly type 2 diabetics in Kinmen, Taiwan. Int J Gerontol. 2014;8(2):95-99.
  24. Grigor’eva IN, Iamlikhanova AIu. Frequency combination of a gallstone disease and diabetes. Eksp Klin Gastroenterol. 2011;4: 99-102.
  25. Pacchioni M, NicolettiC, Caminiti M. Association of obesity and type II diabetes mellitus as a risk factor for gallstones. Dig Dis Sci. 2000;45(10):2002-2006.
  26. Сучкова Е.В. Функциональное состояние гепатобилиарной системы при жировом гепатозе у больных сахарным диабетом. Экспериментальная и клиническая гастроэнтерология. 2009;8:26-29
  27. Koller T, Kollerova J, Hlavaty T. Holelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scandin J Gastroenter. 2012;47(2):197-203.
  28. Zanlungo S, Miquel JF, Rigotti AR. Insulin and cholesterol gallstones: New insights for a complex pathogenic relationship. Hepatology. 2008;48(6):2078-2080.
  29. Nakeeb A, Comuzzie AG, Al-Azzawi H. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg. 2006;10(7): 940-948.
  30. Ruhl СЕ, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatolоgy. 2000;31(20): 299-303.
  31. Chang Y, Sung E, Ryu S. Insulin resistance is associated with gallstones even in non-obese, non-diabetic korean men. J Korean Med Sci. 2008;23(4):644-650.
  32. Kim SS, Lee JG, Kim DW. Insulin Resistance as a Risk Factor for Gallbladder Stone Formation in Korean Postmenopausal Women. Korean J Intern Med. 2011;26(3):285-293.
  33. Cynthia W, Shirley AA. Beresford Scott J et al. Insulin resistance and incident gallbladder disease in pregnancy. Clin Gastroenterol Hepatol. 2008;6(1):76-81.
  34. Biddinger SB, Haas JT, Yu BB. Hepatic Insulin Resistance directly Promotes Formation of Cholesterol Gallstones. Nat Med. 2008;14(7):778-782.
  35. Parker HE, Wallis K, le Roux CW. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol. 2012;165(2):414-423.
  36. Murakami M, Une N, Nishizawa M. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springer Plus. 2013;2(1):20.
  37. Keller J, Trautmann ME, Haber H. Effect of exenatide on cholecystokinin — induced gallbladder emptying healthy subjects. Regul Pept. 2012;179(1-3):77-83.
  38. Gielkens HAJ, Lam WF, Coenraad M. Effect of insulin on basal and cholecystokinin-stimulated gallbladder motility in humans. J Hepatol. 1998;28(4):595-602.
  39. Misciagna G, Guerra V, Di L. Insulin and gall stones: a population case control study in southern. Gut. 2000;47(1):144-147.
  40. Pazzi P, Scagliarini R, Gamberini S. Review article: gall-bladder motor function in diabetes mellitus. Alimentary Pharmacol Therapeutics. 2000;14(2 Suppl.):62-65.
  41. Grigor’eva IN, Iamlikhanova AIu. The role of feeding behaviour hormones in the development of cholelithiasis. Eksp Klin Gastroenterol. 2012;4:43-48.
  42. Agunloye AMI, Adebakin AM, Adeleye JO. Ultrasound prevalence of gallstone disease in diabetic patients at Ibadan, Nigeria. Niger J Clin Pract. 2013;16(1):71-75.
  43. Guraya SY. Reappraisal of the management of cholelithiasis in diabetics. Saudi Med J. 2005;26(11):1691-1694.
  44. Bodmer M, Brauchli YB, Jick SS. Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis. 2011;43(9):742-747.
  45. Raman PG, Patel A, Mathew V. Gallbladder disorders and type 2 diabetes mellitus — a clinic-based study. J Association Physicians of India. 2002;50:887-890.
  46. Физиология. Под ред. Покровского В.М., Коротько Г.Ф. М.: Медицина; 2003.
  47. Weikert C, Weikert S, Schulze MB. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epidemiol. 2010;171(4):447-454.
  48. Губергриц Н.Б., Лукашевич Г.М., Голубова О.А. Панкреатогенный сахарный диабет. Российский журнал гастроэнтерологии, гепатологии, колонопроктологии. 2007;6:11-16.
  49. Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Current Diab Reports. 2014;14(5):482.
  50. Düfer M, Hörth K, Wagner R. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes. 2012;61(6):1479-1489.
  51. Staels B, Fonseca VA. Bile acids and metabolic regulation. DiabetesCare. 2009;32(Suppl 2):237-245.
  52. Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol. 2014;171(2):47-65.
  53. Вахрушев Я.М., Хохлачева Н.А. Роль гормонов в развитии желчнокаменной болезни. Экспериментальная и клиническая гастроэнтерология. 2008;2:57-62.
  54. Sanyal D. Diabetes is predominantly an intestinal disease. Indian J Endocrinol Metab. 2013;17:64-67.
  55. Lerner RL. The augmentation effects of secretin on the insulin responses to known stimuli specificity for glucose. J Clin Endocrinol Metab. 1977;45(1):1-9.
  56. Ткаченко Е.В., Варварина Г.Г. Гормоны пищевого поведения в патогенезе метаболического синдрома. Экспериментальная и клиническая гастроэнтерология. 2008;5:56-59.
  57. Abbott CR. The inhibitory affects of peripheral administration of peptide YY (3—36) and glucagons-like peptide-1 on food intake and attenuated of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005;1044:127-131.
  58. Kojima M, Hosoda H, Date Y. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
  59. Arvat E, Di Vito L, Broglio F. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest. 2000;23:493-495.
  60. Zizzari P, Hassouna R, Grouselle D. Physiological roles of preproghrelin-derived peptides in GH secretion and feeding. Peptides. 2011;32(11):2274-2282.
  61. Korbonits M, Goldstone AP, Gueorguiev Ml. Ghrelin — a hormone with multiple functins. Orv Hetil. 2005;146(25):1345-1351.
  62. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther. 2008;118(2):239-249.
  63. Delhanty PJ, Van der Lely AJ. Ghrelin and glucose homeostasis. Peptides. 2011;32(11):2309-2318.
  64. Dezaki K. Ghrelin function in insulin release and glucose metabolism. Endocr Dev. 2013;25:135-143.
  65. Кириенкова Е.В., Литвинова, Л.С., Селедцов В.И. Метаболические и сердечно-сосудистые эффекты грелина. Ожирение и метаболизм. 2012;1:3-7.
  66. Dezaki K, Yada T. Islet β-cell ghrelin signaling for inhibition of insulin secretion. Methods Enzymol. 2012;514:317-331.
  67. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol. 2002;14(7):555-560.
  68. Otto-Buczkowska E, Chobot A. Role of ghrelin and leptin in the regulation of carbohydrate metabolism. Part I. Ghrelin. PostepyHig Med Dosw (Online). 2012;66:795-798. doi: 10.5604/17322693.1015532// href='http://www.ncbi.nlm.nih.gov/pubmed/23175333' target='_blank'>http://www.ncbi.nlm.nih.gov/pubmed/23175333.
  69. Egido EM, Rodriguez-Gallardo J, Silvestre RA. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol. 2002;146(2):241-244.
  70. Pinkney J. The role of ghrelin in metabolic regulation. Curr Opin Clin Nutr Metab Care. 2014;17(6):497-502.
  71. Tong J, Prigeon RL, Davis HW, Bidlingmaier М. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59(9):2145-2151.
  72. Zhang JV, Ren P-G, Avsian-Kretchmer O. Medicine: obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science. 2005;310(5750):996-999.
  73. Mendes-Sanches N, Ponciano-Rodrigues G, Bermegjo-Martines L. Low serum levels of ghrelin are assosiated with gallstone disease. World J. Gastroenterol. 2006;12(19):3096-3100.
  74. Feighner SD, Tan CP, McKee KK. Receptor for motilin identified in the human gastrointestinal system. Science. 1999;284(5423): 2184-2188.
  75. Терещенко И.В., Каюшев П.Е., Зубарева Н.А. Отличия течения сахарного диабета в зависимости от сроков проявления желчнокаменной болезни. II Всерос. Конгресс «Инновационные технологии в эндокринологии» с участием стран СНГ: Сборник тезисов. М.; 2014:130.
  76. Cheung GW, Kokorovic A, Lam CK. Diabetes and cholecystokinin. J Cell Metab. 2009;10(2):99-109.
  77. Miyamoto S, Shikata K, Miyasaka K. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes. 2012;61(4):897-907.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies